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Abstract: ”Novel Approach to Study Virus - Host Interactions in the Prototypic Murine Infection
Model of Lymphocytic Choriomeningitis Virus” Andreas Bergthaler Das Arenavirus Lymphozytäre-
Choriomeningitis-Virus (LCMV) war eines der Standardmodelle für Virusimmunologen in den letzten
Jahrzehnten. Sein zweisegmentiges negativsträngiges RNA Genom hat dabei aber ein großes Hindernis
dargestellt für die Bemühungen, das Virusgenom mittels reverser Genetik zu manipulieren. Hier zeigen
wir die Generierung von infektiösem LCMV (Stamm Armstrong Clone 13) komplett aus cDNA. Intrazel-
luläre Transkription des langen und des kurzen Segments durch Polymerase-I Vektoren sowie Koxpression
der minimal-notwendigen viralen trans-acting Elemente NP und L von Polymerase-II Plasmiden führte zu
der effizienten Bildung von infektiösem Virus mit genetischen Markierungen in seinen beiden Genomseg-
menten. Die aus cDNA generierten Viren verhielten sich ident zum Wildtypvirus sowohl in Zellkultur als
auch in infizierten Mäusen. Dabei führten sie -wie das Wildtypvirus- zu einer chronischen Infektion und
supprimierten die adaptive Immunantwort gegenüber einem nichtverwandten Virus. Diese Technologie
liefert die Basis für die Erforschung von viralen Determinanten für persistente Infektionen und Immun-
suppression. Zusätzlich demonstrieren unsere Ergebnisse, daß Polymerase-I/-II basierende Vektorsysteme
eine effiziente alternative Strategie für die Generierung von zytoplasmatischen negativsträngigen RNA
Viren aus cDNA darstellen. The prototypic arenavirus lymphocytic choriomeningitis virus (LCMV)
has represented a primary workhorse of viral immunologists for almost a century, and it has served as
an important model to study basic principles of the arenavirus molecular biology. Its negative-stranded
bisegmented RNA genome had however posed a major obstacle to attempts at manipulating the infectious
virus by reverse genetic techniques. Here we report the recovery of infectious LCMV (strain Armstrong
clone 13) entirely from cDNA. Intracellular transcription of the short and the long viral genome segment
from polymerase I-driven vectors and coexpression of the minimal viral trans-acting factors NP and L
from polymerase II-driven plasmids resulted in the efficient formation of infectious virus with genetic
tags in the viral genome segments. The cDNA-derived viruses behaved identical to wild type virus, both
in cell culture and in infected mice. Importantly, they caused a chronic infection and suppressed the
adaptive immune response to an unrelated third party virus. This technology provides an important
basis to investigate viral determinants of persistent infection and immunosuppression. In addition, our
findings demonstrate that polymerase I-/II-based vector systems may represent an efficient alternative
strategy for the recovery of cytoplasmic negative- strand RNA viruses from cDNA.
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Summary 
 
The prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) has 
represented a primary workhorse of viral immunologists for almost a century, 
and it has served as an important model to study basic principles of the 
arenavirus molecular biology. Its negative-stranded bisegmented RNA 
genome had however posed a major obstacle to attempts at manipulating the 
infectious virus by reverse genetic techniques.  
Here we report the recovery of infectious LCMV (strain Armstrong clone 13) 
entirely from cDNA. Intracellular transcription of the short and the long viral 
genome segment from polymerase I-driven vectors and coexpression of the 
minimal viral trans-acting factors NP and L from polymerase II-driven 
plasmids resulted in the efficient formation of infectious virus with genetic tags 
in the viral genome segments. The cDNA-derived viruses behaved identical to 
wild type virus, both in cell culture and in infected mice. Importantly, they 
caused a chronic infection and suppressed the adaptive immune response to 
an unrelated third party virus. This technology provides an important basis to 
investigate viral determinants of persistent infection and immunosuppression. 
In addition, our findings demonstrate that polymerase I-/II-based vector 
systems may represent an efficient alternative strategy for the recovery of 
cytoplasmic negative-strand RNA viruses from cDNA.  
 
 
 
 
Zusammenfassung 
 
Das Arenavirus Lymphozytäre-Choriomeningitis-Virus (LCMV) war eines der 
Standardmodelle für Virusimmunologen in den letzten Jahrzehnten. Sein 
zweisegmentiges negativsträngiges RNA Genom hat dabei aber ein großes 
Hindernis dargestellt für die Bemühungen, das Virusgenom mittels reverser 
Genetik zu manipulieren. 
Hier zeigen wir die Generierung von infektiösem LCMV (Stamm Armstrong 
Clone 13) komplett aus cDNA. Intrazelluläre Transkription des langen und des 
kurzen Segments durch Polymerase-I Vektoren sowie Koxpression der 
minimal-notwendigen viralen trans-acting Elemente NP und L von 
Polymerase-II Plasmiden führte zu der effizienten Bildung von infektiösem 
Virus mit genetischen Markierungen in seinen beiden Genomsegmenten. Die 
aus cDNA generierten Viren verhielten sich ident zum Wildtypvirus sowohl in 
Zellkultur als auch in infizierten Mäusen. Dabei führten sie –wie das 
Wildtypvirus- zu einer chronischen Infektion und supprimierten die adaptive 
Immunantwort gegenüber einem nichtverwandten Virus. Diese Technologie 
liefert die Basis für die Erforschung von viralen Determinanten für persistente 
Infektionen und Immunsuppression. Zusätzlich demonstrieren unsere 
Ergebnisse, daß Polymerase-I/-II basierende Vektorsysteme eine effiziente 
alternative Strategie für die Generierung von zytoplasmatischen 
negativsträngigen RNA Viren aus cDNA darstellen. 
 
Recovery of an arenavirus entirely from RNA
polymerase III-driven cDNA
Lukas Flatz†‡, Andreas Bergthaler†‡, Juan Carlos de la Torre§, and Daniel D. Pinschewer†¶
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Communicated by Rolf M. Zinkernagel, University Hospital of Zu¨rich, Zu¨rich, Switzerland, January 31, 2006 (received for review December 27, 2005)
The prototypic arenavirus lymphocytic choriomeningitis virus has
been a primary workhorse of viral immunologists for almost a
century, and it has served as an important model for studying basic
principles of arenavirus molecular biology. Its negative-stranded
bisegmented RNA genome has, however, posed a major obstacle
to attempts at manipulating the infectious virus by reverse genetic
techniques. Here, we report the recovery of infectious lymphocytic
choriomeningitis virus (the immunosuppressive strain clone 13)
entirely from cDNA. Intracellular transcription of the short and the
long viral genome segment from polymerase (pol) I-driven vectors
and coexpression of the minimal viral-transacting factors NP and L
from pol II-driven plasmids resulted in the efficient formation of
infectious virus with genetic tags in both genome segments. The
cDNA-derived viruses behaved identically to wild-type virus in
both cell culture and infected mice. Importantly, they caused a
chronic infection and suppressed the adaptive immune response to
an unrelated third-party virus. This technology provides an impor-
tant basis for investigating viral determinants of persistent infec-
tion and immunosuppression. In addition, our findings demon-
strate that pol III-based vector systems may represent an efficient
alternative strategy for the recovery of cytoplasmic negative-
strand RNA viruses from cDNA.
immunosuppression  lymphocytic choriomeningitis virus  reverse genetics 
negative-strand RNA virus
The prototypic arenavirus lymphocytic choriomeningitis virus(LCMV) was first isolated in the 1930s (1, 2). Ever since, it
has served as a primary workhorse in the fields of immunology
and viral pathogenesis, contributing substantially to the devel-
opment of multiple key concepts in both disciplines (reviewed in
ref. 3). Among its many interesting aspects, LCMV has been
particularly instrumental in the investigation of antiviral toler-
ance and virus-induced immunosuppression in persistent infec-
tion. Moreover, this virus may represent a neglected human
pathogen (4). Over the years it has been found that, in addition
to LCMV, a substantial number of other arenaviruses are widely
distributed in the rodent populations of the entire world. Some
of them, e.g., Lassa fever virus, a close relative of LCMV, and
the New World viruses Junin, Machupo, and Guanarito, are of
particular interest because they can cause hemorrhagic fevers
with high lethality when accidentally transmitted to humans (5).
Arenavirus genomes consist of two single-stranded RNA
segments, each of them encoding for two viral genes in am-
bisense orientation, separated by an intergenic region (IGR) that
is predicted to fold into a secondary RNA structure of high
stability. The short segment (S segment) expresses the viral
surface glycoprotein (GP) and the nucleoprotein (NP) that
encapsidates the viral genome and replicative intermediates
(Fig. 1A). The long segment (L segment) carries the genes for the
viral RNA-dependent RNA polymerase (pol) L and the small
matrix protein Z. Despite their ambisense coding strategy,
however, arenaviruses are negative-strand viruses, i.e., transfec-
tion of purified viral RNA into permissive cells does not initiate
an infectious cycle, a fact that has long impeded the analysis of
arenavirus molecular biology. Only relatively recently, a mini-
replicon system has been developed, allowing for the analysis of
the viral cis-acting elements and transacting factors involved in
transcription, replication, and particle formation (6–10), and
similar systems have subsequently been described for Tacaribe
virus and Lassa fever virus (11, 12). The LCMV reverse genetic
system had initially been based on the intracellular expression of
a viral model genome (MG) from T7 RNA pol (T7), combined
with either T7-driven or pol II-driven coexpression of the
minimal viral-transacting factors NP and L (6, 7). Owing to the
virus’s cytoplasmic life cycle, T7 had been the obvious choice for
expression of an LCMV genome analogue. For orthomyxovi-
ruses with a nuclear life cycle, however, pol I-driven vectors had
long been accepted as a powerful method for expressing MGs
and later for the efficient recovery of infectious viruses entirely
from plasmid (reviewed in ref. 13). Stimulated by findings made
in the bunyavirus field (14), we have also documented that pol
I-driven vectors represented an efficient alternative means for
expressing LCMV MG RNAs (9). Pol I-derived MG RNA
species were exported to the cytoplasm where they assembled
with plasmid-supplied L and NP proteins into ribonucleopro-
teins (RNPs) that were active in cytoplasmic transcription and
replication (9). This system could even be exploited to recon-
stitute a recombinant full-length S-segment RNP. Upon reas-
sortment with helper virus as a source for the L segment, an
infectious LCM virus with an engineered S segment was recov-
ered that expressed the GP of vesicular stomatitis virus (VSV)
instead of the LCMV-GP (rLCMVVSVG, ref. 15). In a reverse
reassortment process, the VSVG-expressing S segment of this
virus could be exchanged for a cDNA-derived S segment of
interest, a strategy that was vastly facilitated by the potent
selective capacity of VSV-neutralizing antibodies. Accordingly,
viruses generated by this method have allowed us to study the
role of the viral GP in liver disease (A.B., D. Merkler, E.
Horvath, L. Bestmann, and D.D.P., unpublished work) and
GP-based strategies to attenuate arenaviruses for use as live
vaccines (A.B., N. U. Gerber, D. Merkler, E. Horvath, J.C.d.l.T.,
and D.D.P., unpublished work). Yet the arenavirus L segment
harbors key determinants of the viral phenotype (16) that could
not be studied in a reverse genetic manner. Here, we report that
the intracellular expression of the LCMVRNA genome from pol
I-driven vectors, combined with pol II-driven coexpression of the
minimal transacting factors NP and L, resulted in the efficient
recovery of infectious LCMV entirely from cDNA. This finding
shows that pol I-driven systems may represent an efficient
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5
alternative for the recovery of cytoplasmic negative-strand RNA
viruses from cDNA. Moreover, the technology presented here
and a simultaneously developed T7-driven system for the recov-
ery of LCMV from cDNA (34) will provide powerful reverse
genetic approaches for the study of the arenavirus immunobi-
ology by using genetically engineered replication-competent
viruses.
Results
We had observed that an LCMV L segment-based MG of 7.6
kb could be expressed from a pol I-driven vector and yielded
reporter gene activity when the viral-transacting factors were
coexpressed (D.D.P. and J.C.d.l.T., unpublished work). This
finding lent support to the hypothesis that pol I should be able
to express not only a full-length S segment (15) but also the L
segment of LCMV (7.2 kb in length) for recognition by the
viral-transacting factors. Thus, we set out to extend our previ-
ously published pol III-driven reverse genetic system for LCMV
(9, 10, 15) to allow for the recovery of infectious virus entirely
from plasmid. The previously publishedMG system and a partial
rescue system for LCMV had been based on the Armstrong
(ARM)53b strain (6, 9) that is unable to establish persistence in
adult mice (17–19). With the intention of studying the virus–host
relationship during chronic infection we therefore attempted to
establish a complete rescue system for the ARM-derived variant
clone 13 [Cl13 (17)] rather than for ARM itself.We first revisited
the published Cl13 sequence [GenBank accession no. DQ361065
(S segment) andGenBank accession no. DQ361066 (L segment),
compare with GenBank accession nos. M64450, J04331, and
M27693, and ref. 20; for technical details see Supporting Text,
which is published as supporting information on the PNAS web
site] with an emphasis on the noncoding sequences of the L
segment. The L-segment IGR (L-IGR) had previously been
reported to exhibit substantial variability in length (21). Con-
sidering the important roles of the S-segment IGR in the viral life
cycle (10), we reasoned that a correct L-IGR sequence was likely
of importance for the efficient recovery of LCMV from plasmid.
To overcome the intrinsic difficulties related to the predicted
secondary RNA structures in the L-IGR, we used a heat-stable
reverse transcription (RT) pol with helicase activity, followed by
PCR amplification (for details see Supporting Text). Sequence
analysis of the obtained PCR product readily yielded an L-IGR
consensus sequence that was of the same length, although not of
identical sequence, as the one recently published for LCMV-
ARM53b (GenBank accession no. DQ361066, compare with
GenBank accession nos. AY847351 and AY894816).
It had been demonstrated that arenavirus S segments carry a
nontemplated G residue at their 5 ends (22), but the precise 5
terminus of the LCMV L segment was less certain (21, 23). For
a Lassa fever virus S segment analogue it had, however, been
shown that efficient template recognition by the viral RNA-
dependent RNA pol depended critically on the precise 5 end
(12), and we have made similar observations for the LCMV S
segment (ref. 8 and D.D.P and J.C.d.l.T. unpublished work).
Thus, we analyzed the Cl13 L segment 5 ends by using a 5
RACE protocol that was based onA-tailing of first-strand cDNA
with terminal deoxynucleotidyl transferase (for technical details
see Supporting Text). This approach unambiguously revealed a G
residue at position 1 on both the LCMV L-segment genome
and antigenome (Fig. 1B). Different investigators (24–26) have
unequivocally shown that the 3 end of the L-segment genome
terminates on a G residue and not on a C (Fig. 1 C and D). Thus,
intramolecular annealing of the genome into a panhandle struc-
ture [the putative viral promoter (8), Fig. 1C] does not form a
flush end as for most negative-strand RNA viruses (22). Also,
this finding suggests that the 5 G of antigenomes found here
represents a nontemplated base like in the S segment (ref. 22 and
Fig. 1D). An analogous conclusion for the L-segment genome 5
G, although likely, however, awaits formal determination of its
template, i.e., of the antigenome 3 end.
Based on this sequence information we assembled Cl13 S- and
L-segment cDNAs containing the master consensus sequence
and cloned them in genomic polarity under control of the mouse
pol I promoter and terminator cassettes (14). Thereby we
obtained the plasmids pI-S-Cl13()* and pI-L-Cl13(), respec-
tively (Fig. 1E). pI-S-Cl13()* was partially based on a previ-
ously published backbone [pS-Bsm() (15)] that contained a
noncoding single-nucleotide tag, deleting an EcoNI site for
discrimination from wild-type virus (Fig. 2C). In contrast, pI-
L-Cl13() was assembled de novo and did not contain a genetic
tag. A second constructs was also generated [pI-L-Cl13()*,
Fig. 1E] that differed from the wild-type Cl13 (wtCl13) sequence
by a noncoding single-nucleotide transition in the Z ORF.
Thereby an additional AvaII recognition site was introduced
(Fig. 2C). The NP ORFs of ARM53b and Cl13 are identical, and
hence the available pol II-driven expression plasmid pC-NP (7)
could also be used here for intracellular coexpression of this viral
protein. The previously published plasmid for intracellular ex-
Fig. 1. Sequence of the LCMV L-IGR and 5 terminus and genome expression
vectors. (A) Schematic of the bisegmented LCMV genome with its four known
genes (arrows). Inverted writing indicates antisense polarity. (B) Sequence
analysis of the L-segment 5 end was carried out as described in Supporting
Text. The first-strand cDNA (cDNA) was A-tailed at its 3 end for amplification
by PCR and subsequent sequence analysis. The deducted 5 terminal template
sequence of the L-segment genome and antigenome, respectively, and their
nucleotide positions are indicated (1 to 9). Note the 5 nontemplated G at
position 1. (C) Intrasegment base-pairing and panhandle formation of the
L-segment 5 and 3 terminal nucleotides with positions indicated. (D) Com-
parison of the L-segment antigenome 5 end with its template, the L-segment
genome 3 terminus. Nucleotide positions are indicated. (E) Schematic de-
scription of the genome expression vectors used in this study. Noncoding
genetic tags are indicated by *, cis-acting elements are boxed, and ORFs are
labeled and represented as arrows. Inverted writing indicates antisense po-
larity. pol-I-P, pol I promoter; pol-I-T, pol I terminator.
4664  www.pnas.orgcgidoi10.1073pnas.0600652103 Flatz et al.
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pression of the ARM53b L ORF under control of pol II [pC-L
(7)] differed, however, from our Cl13 sequence at four coding
positions, and hence a plasmid was generated (pC-Cl13-L)
expressing the Cl13 L ORF (master consensus sequence) under
control of the same pol II expression cassette (27).
As schematically depicted in Fig. 2A, cotransfection of BHK-21
cells with pC-NP, pC-Cl13-L, pI-S-Cl13()*, and either pI-L-
Cl13() or pI-L-Cl13()* resultedwithin72–96h in the recovery
of high titers of infectious virus from the culture supernatant (Fig.
2B). Notably, this result was obtained at the first try by using
standard lipofection procedures.Moreover, the recovery was highly
reproducible i.e., from a total of 30 individual M6 tissue culture
wells that were transfected in multiple experiments all but one
yielded infectious virus, underscoring the high efficiency of the
system. To ascertain the viral origin from cDNA we tested for the
presence of the genetic tags in the viral genome. The virus obtained
when transfecting pI-S-Cl13()* and pI-L-Cl13() will be referred
to as rCl13*, whereas the virus derived from pI-S-Cl13()* and
pI-L-Cl13()*was named rCl13** to indicate the expected genetic
tags in only one or both genome segments, respectively. Fresh
BHK-21 cells were infected with rCl13*, rCL13**, or wtCl13 for
comparison, and RT-PCRs were carried out to amplify viral RNA
stretches spanning the expected genetic tags in the S and L
segments (schematically depicted in Fig. 2C). All PCR products
were RT-dependent, excluding residual plasmid contamination in
the virus preparations that might have confounded the subsequent
analysis (Fig. 2D). As expected, the S segment-derived amplifica-
tion product of wtCl13 was sensitive to digestion with EcoNI,
whereas the products derived from rCl13* and rCl13** were not.
The L segment-derived RT-PCR products of wtCl13 and rCl13*
yielded identical fragments when digested with AvaII, whereas
rCl13** yielded smaller ones as predicted (Fig. 2C). Hence, rCl13*
and rCl13** were derived from the transfected parental plasmids.
Next, we compared the growth curves of rCl13* and rCl13**
with wtCl13 in cell culture and found them to be indistinguishable
(Fig. 3A). To also compare viral replication kinetics in vivo,
C57BL6 mice were infected i.v. with 2 106 plaque-forming units
(PFU) of wtCl13, rCl13*, rCl13**, or ARM53b as a control virus
that is unable to persist in adult mice. Upon infection with wtCl13,
rCl13*, or rCl13**, high-titer viremia was established within 4 days,
lasting for at least 29 days. In contrast, ARM53b was cleared from
the blood within 8 days after infection. We also verified that the
viral populations persisting in rCl13*- and rCl13**-infected mice
still carried the genetic tags. Viral RNA was extracted from the
serum ofmice at day 12 after infection, andRT-PCRproducts were
tested by restriction digestion as outlined above. The analysis
yielded the same result as shown in Fig. 2D for tissue culture
infections, confirming that the genetic tags were stably expressed
(Fig. 5, which is published as supporting information on the PNAS
web site).
Persistent infection with Cl13 is known to subvert both the
LCMV-specific CTL response to immunodominant epitopes and
the adaptive immune response to unrelated third-party infec-
tions (18, 28). To test whether the cDNA-derived viruses shared
the ability of wtCl13 to cause such an acquired immunodefi-
ciency syndrome, the above groups of mice and uninfected
controls were challenged with 2  106 PFU of VSV i.p. on day
22 after primary infection (Fig. 4). Serum was collected on days
25 and 29 (i.e., days 3 and 7 after VSV challenge, respectively)
to determine VSV-neutralizing antibody titers. ARM-infected
mice mounted virtually unimpaired IgM responses on day 25,
followed by isotype class switch and neutralizing IgG titers on
yielded the expected fragments upon digestion with AvaII or EcoNI, respec-
tively (Middle), and were fully RT-dependent (compare with RT, Bottom).
Single-headed arrow: undigested PCR product; double-headed arrow: di-
gested fragments; feathered arrow: primer dimers.
Fig. 2. Recovery of genetically tagged Cl13 entirely from cDNA. (A and B) As
outlined schematically in A, subconfluent BHK-21 cells in M6 tissue culture
wells were transfected with 0.8 g of pC-NP, 1 g of pC-Cl13-L, 0.8 g of
pI-S-Cl13()*, and either 1.4 g of pI-L-Cl13() to recover rCl13* or 1.4 g
of pI-L-Cl13()* to recover rCl13**. In negative control wells [without (wo)
pI-S-Cl13()*], the pI-S-Cl13()* plasmid was substituted for an MG expres-
sion plasmid lacking LCMV structural genes and expressing GFP instead (9). (B)
Culture supernatant was collected at the indicated time points and tested for
viral infectivity by immunofocus assays. Symbols represent individual culture
wells. (C) Schematic description of the genetic tags in the S- and L-segment
cDNAs. The stretches of viral RNA amplified by RT-PCR and the predicted
fragments obtained from restriction digestion are indicated. (D and E) Fresh
BHK-21 cells were infected with wtCl13, rCl13*, and rCl13** at multiplicity of
infection of 0.1 or left uninfected (none). Forty-eight hours later, total cellular
RNA was harvested and processed for RT-PCR amplification. L segment-
specific (D) and S segment-specific (E) amplification products (RT, Top)
Flatz et al. PNAS  March 21, 2006  vol. 103  no. 12  4665
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day 29 that were in a similar range as in mice that had not
undergone prior infection with LCMV (Fig. 4A). In marked
contrast, these responses were suppressed to below detection
levels in mice that were persistently infected with wtCl13, rCl13*,
or rCl13**. The early IgM response (i.e., day 3 after VSV
infection) is known to be T cell-independent, whereas isotype
class switch and the production of IgG is CD4T cell-dependent,
indicating that the cDNA-derived viruses rCl13* and rCl13**
shared the ability of wtCl13 to suppress both of these immune
functions. Moreover, persistent infection with one of these three
viruses caused a marked suppression of the VSV-specific CD8
T cell response, whereas ARM infection did not (Fig. 4B). As
expected, persistent infection with wtCl13, rCl13*, or rCl13**
also resulted in the exhaustion of the CD8 T cell response to the
immunodominant LCMV epitope NP396, whereas NP396-
specific IFN--producing CD8 T cells were readily detected in
ARM-infected mice (Fig. 4B). Taken together, the in vivo
behavior of the cDNA-derived and genetically tagged rCl13*
and rCl13** viruses was indistinguishable from wtCl13, validat-
ing our pol I-based reverse genetic system for the analysis of the
virus–host relationship in adult persistent LCMV infection.
Importantly, two viruses recovered from different L-segment
expression plasmids (rCl13* and rCl13**) exhibited an identical
phenotype. This is an additional indication for the high repro-
ducibility of our reverse genetic system, a property that will be
of paramount importance for future studies addressing the
impact of individual point mutations on viral immunobiology.
Discussion
Unlike for all of the other known families of negative-strand RNA
viruses (13, 29), arenaviruses have to our knowledge not previously
been recovered entirely from cloned cDNA, and the same seems to
be the case for bona fide ambisense viruses. With this study and a
simultaneous study by Sanchez and de la Torre (34), these hurdles
have been overcome. Here, we have exploited pol I-driven vectors
for expression of the viral genome segments, a strategy that is
against current practice for a cytoplasmic virus like LCMV. A
T7-based rescue system, as exploited byA. B. Sanchez and J.C.d.l.T.
(34), would have represented the obvious method of choice. It has
been known for a while, however, that viruses with a nuclear life
cycle such as influenza A can be recovered by using either T7- or
pol I-driven systems (13). As shown here, the same holds true for
cytoplasmic viruses. This possibility had previously been suggested
by pol I-based MG systems for bunyaviruses, filoviruses, and
arenaviruses (9, 14, 30), but a complete pol I-based rescue of an
infectious negative-strand virus with a cytoplasmic life cycle has to
our knowledge not previously been reported. The rescue system of
choice for a particular virus may therefore not depend only on its
intracellular compartment of replication. The differential prone-
ness of T7 or pol I to terminate prematurely at terminator-like
sequences within a given viral genome may represent only one of
many factors that may be difficult to predict but could substantially
influence the efficiency of virus recovery. In addition, pol I-based
systems render the use of a 3 terminal ribozyme unnecessary
Fig. 3. Propagation of cDNA-derived viruses in cell culture and infected mice.
(A) Subconfluent BHK-21 cells in M6 tissue culture wells were infected with
wtCl13, rCl13*, or rCl13** at multiplicity of infection of 0.01. Supernatant was
collected at the indicated time points for determination of viral titers. Symbols
represent the mean  SD of three individual culture wells. (B) C57BL6 mice
were infected with 2 106 PFU of ARM53b, wtCl13, rCl13*, or rCl13**. Blood
was collected at the indicated time points for the assessment of viral titers.
Symbols represent the mean SD of four mice per group. One representative
experiment of two is shown.
Fig. 4. Suppression of B cell and T cell responses by the cDNA-derived viruses.
On day 0, C57BL6 mice (same mice as in Fig. 3B) were infected i.v. (1°
infection) with 2  106 PFU of ARM53b, wtCl13, rCl13*, or rCl13**, or they
were left uninfected (none). Twenty-two days later, the indicated groups of
mice were challenged with 2  106 PFU of VSV i.p. (2° infection). (A) On days
25 and 29 (3 and 7 days after secondary infection), serum samples were
collected for determination of VSV-neutralizing IgM (day 25) and neutralizing
IgG (day 29). Symbols represent individual mice. One representative experi-
ment of two is shown. (B) On day 30, the mice were killed, and the frequency
of splenic IFN--producing CD8 T cells specific for either the immunodomi-
nant VSV NP-derived epitope NP52 or the LCMV NP-derived epitope NP396
was determined in an intracellular cytokine assay. Background IFN- produc-
tion is shown for comparison (unstimulated). The frequency of IFN--
producing CD8 cells within the total CD8 T cell compartment is indicated for
each representative FACS plot. Numbers indicate the mean SD of three mice
per group.
4666  www.pnas.orgcgidoi10.1073pnas.0600652103 Flatz et al.
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because, unlike for T7, transcription termination at the pol I
terminator is of high precision. Ribozymes, however, can be of
limited cleavage efficiency requiringmodifications on the transcript
3 terminus (8). In favor of T7-driven systems speaks their func-
tionality in virtually any cell type, whereas pol I expression cassettes
are relatively species-specific, e.g., the vector used here operates
almost exclusively in rodent cells. Furthermore, the use of a pol
III-driven system bears the potential risk for unintentional splicing
of the primary transcripts, which may prevent the successful appli-
cation of our rescue strategy to specific arenaviruses or strains.
We have expressed viral RNA segments of genomic () polarity
bearing the potential risk of hybrid arrest, i.e., the annealing of L-
and NP-mRNAs with the unencapsidated genomic L- and S-
segment RNAs, respectively. It had been proposed that this process
could prevent ribonucleoprotein formation and thereby the initia-
tion of the infectious cycle. The efficient recovery of virus by using
genomic polarity transcripts does not exclude that hybrids form, but
it suggests that hybrid arrest was not a major limiting factor in this
setting. Preliminary data suggest, however, that virus can also be
recovered when RNA of antigenomic polarity is expressed (data
not shown). For future attempts at rescuing other arenaviruses from
cDNA, it may be worth trying both polarities in parallel to enhance
the likelihood that other potential pitfalls like terminator-like
sequences in the transcript (see above) can be avoided.
The LCMV rescue system for Cl13 presented here and the
T7-driven LCMV rescue system (34) should enable us to tackle
a number of long-standing questions about the virus’s molecular
biology, its relationship with the host cell, and the specific role
of the four known viral genes in various models of viral patho-
genesis (3, 16, 18, 19). Chronic infection with Cl13 represents one
of the prototypical small-animal models for investigating basic
mechanisms of T cell dysfunction in chronic infection and viral
interference with antigen presentation as a substrate of virus-
induced immunosuppression (18, 19). The ability for directed
engineering of the entire LCMV genome will offer unique
opportunities for investigating the viral determinants thereof
and studying the immunological pressure exerted on the persist-
ing virus. In addition, the methodology and vector combinations
used here should allow for the rescue of other arenaviruses,
including Lassa fever virus and the South American hemorrhagic
fever viruses, from plasmid. This technology may accelerate the
development and fine-tuning of live-attenuated arenavirus vac-
cines (16) and may substantially facilitate their safe production
for use in endemic areas where they are urgently needed (5, 31).
Materials and Methods
Plasmids, Cells, and Transfections. The pC-NP plasmid has been
described (7, 8). For generation of pC-L-Cl13, the Cl13 L ORF
was amplified by RT-PCR in three separate fragments that were
merged for insertion into the pC backbone (27), analogously to
a strategy described for Lassa fever virus (ref. 12 and see Fig. 6,
which is published as supporting information on the PNAS web
site). pI-S-Cl13()* was generated by inserting a Cl13-GP
cDNA into the pS-Bsm() backbone that expresses under the
control of pol I a LCMV S-segment cDNA with a linker instead
of the GP ORF (15). pI-L-Cl13() is based on the same pol I
vector as pI-S-Cl13()* (14) and was assembled in a multistep
cloning procedure from RT-PCR fragments with master con-
sensus sequence (for details of the cloning strategy see Fig. 6;
primers used for cloning of the L-segment constructs are listed
in Table 1, which is published as supporting information on the
PNAS web site). The AvaII site in the Z ORF was introduced in
a standard two-way PCR approach. Additional primer sequences
and PCR conditions are available on request. BHK-21 cells were
transfected by using Lipofectamin (3 lg DNA; Invitrogen).
Viruses, Viral Immunofocus Assay, and Identification of Genetic Tags.
The ARM-derived variant Cl13 (17) was obtained from Rafi
Ahmed (Emory Vaccine Center, Atlanta), and passage 5 was
used for RT-PCR cloning and mouse experiments. ARM53b was
obtained from Michael Buchmeier (The Scripps Research In-
stitute). LCMV titers were determined in a NP-specific immuno-
focus assay as described (32).
For identification of the genetic tags, total cellular RNA was
extracted from virus-infected cells by using Trizol (Invitrogen) or
from mouse serum by using the QIAamp viral RNA mini kit
(Qiagen, Valencia, CA). RTwas carried out with randomhexamers
by using Superscript II RT pol (Invitrogen), and Taq pol (NEB,
Beverly, MA) was used for PCR with gene-specific primers
5-GCATTGTCTGGCTGTAGCTTA-3 and 5-CAATGAC-
GTTGTACAAGCGC-3 for the S segment or with primers
5-TATGAAGACAGAGGTGCGCACCGGGGATCCTAGGC-
GTTTAG-3 (unpaired overhang in italics) and 5-CTTCG-
TAGGGAGGTGGAGAG-3 for the L segment. EcoNI or AvaII
digestion of the PCR products was performed without prior puri-
fication, which explained occasionally incomplete digestion.
Mice and Animal Experiments. C57BL6 mice were bred at the
Institut fu¨r Labortierkunde at the University of Zurich and
housed under specific pathogen-free conditions for the experi-
ments. All animal studies were carried out with authorization by
the Kantonale Veterina¨ramt and in accordance with Swiss law
for animal protection.
Intracellular Cytokine Assay and VSV Neutralization Assays. Peptide
stimulation and intracellular staining for IFN- have been
described (33). Anti-CD8-phycoerythrin and anti-IFN--
allophycocyanin were purchased from Pharmingen. VSV neu-
tralization assays were carried out as described (32). Neutralizing
IgG was measured by 2-mercaptoethanol resistance because
secondary antibodies could not be used (32). Neutralizing
activity exceeding the 2-mercaptoethanol-resistant fraction by
4-fold or more was considered IgM.
Viral Sequence Analysis. Sequencing protocols are outlined in
detail in Supporting Text. Briefly, Cl13 virion RNA was purified,
and cDNA was generated with gene-specific primers by using
superscript II RT pol (Invitrogen) or Omniscript RT pol (Qia-
gen) for the L-IGR. PCR was carried out with PFU Turbo
(Stratagene) or Amplitaq Gold (PerkinElmer) for the L-IGR.
PCR products were either sequenced directly or first cloned into
the pGEMT vector (Promega). The S-segment terminal se-
quences were determined by a RNA circularization-based pro-
tocol. For 5RACE analysis of the L-segment termini, protocols
were adapted from the Invitrogen kit manual, 3RACE System
for Rapid Amplification of cDNA Ends.
We thank Urs Schneider, Rima Youil, and Mar Perez for helpful discus-
sions; Edit Horvath for excellent technical assistance; and Dieter
Zimmermann for sequencing services. A.B. holds a Ph.D. fellowship from
the Boehringer Ingelheim Fonds. This work was supported by Swiss
National Science Foundation Grant 3100A0-1040671 (to D.D.P.).
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